High-Dose Anti-VEGF: Cross-Trial Analysis of Different Doses and Antagonists for the Treatment of Diabetic Macular Edema

Related

• 

  Percentage of Patients Maintained on Quarterly Anti-VEGF Dosing for the Treatment of Neovascular Age-Related Macular Degeneration

  David A. Eichenbaum, MD, FASRS

  Updates from the Field

  2018

• 

  Expert Panel: Faricimab and Aflibercept 8 mg in AMD

  John T. Thompson, MD

  Andrew A. Moshfeghi, MD, MBA, FASRS

  Manjot K Gill, MD, FASRS

  Christina Y Weng, MD, MBA, FASRS

  Ferhina S Ali, MD, MPH

  Ian Pearce, MB ChB BSc FRCOPHTH

  Annual Meeting Talks

  2024

• 

  Randomized, Prospective, Double-Masked, Controlled Phase 2b Trial to Evaluate the Safety and Efficacy of ALG-1001 (Luminate®) in Diabetic Macular Edema

  Peter K. Kaiser, MD FASRS

  Annual Meeting Talks

  2018